Condition
Split-thickness Skin Graft Donor Sites
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Completed2
Withdrawn2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00392301WithdrawnPrimary
Split-Thickness Skin Graft Donor Site Wound Healing Study
NCT02642679Not ApplicableCompletedPrimary
Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects
NCT02712164Not ApplicableWithdrawnPrimary
Molecular, Histologic, and Clinical Analysis of Negative Pressure Wound Therapy (NPWT) for Split-thickness Skin Graft (STSG) Donor Sites
NCT01512017Phase 3CompletedPrimary
Clinical Study on Veloderm for the Treatment of Split-thickness Skin Graft Donor Sites
Showing all 4 trials